Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Remaining parasitaemic at 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT leads to lower remaining parasitaemic at 24 hours compared with CQ (high certainty).
1 finding from 1 review
Remaining febrile after 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT probably leads to lower remaining febrile after 24 hours compared with CQ (moderate certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in effective treatment of the blood stage parasite As assessed by:… compared with CQ (high certainty).
1 finding from 1 review
Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56/63 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with CQ (low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P probably leads to lower effective treatment of the blood stage parasite As assessed by:… compared with alternative ACTs (moderate certainty).
1 finding from 1 review
Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with alternative ACTs (low certainty).
1 finding from 1 review
Outcomes · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations needing hospitalisation · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations requiring oral corticosteroids ‐ adults · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with exacerbations requiring oral steroids compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.75 [0.65, 0.87]
9096 participants
High
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
OR 0.92 [0.74, 1.13]
9130 participants
Moderate
Patients with severe exacerbations (requiring hospitalisation or ER visit) · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with severe exacerbations (requiring hospitalisation or ER… compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.72 [0.57, 0.9]
7768 participants
High